Avadel Pharmaceuticals ADR Logo
US05337M1045
A2DJR8
AVDL

Avadel Pharmaceuticals ADR

Cargando cotizaciones...

Previsión

El precio objetivo medio de los analistas es de 18,50 € (+1,48 %). La mediana es de 17,26 € (-5,32 %).

Comprar
  8
Mantener
  6
Vender
  0

  • TIG Advisors reports 4.18% stake in Avadel Pharmaceuticals

    TIG Advisors disclosed a 4.18% stake in Avadel Pharmaceuticals, holding 4,102,946 common shares. On January 15 the firm acquired 251,499 shares at prices between $21.50 and $21.53 per share. The filing states that TIG Advisors holds no short positions or Avadel‑related derivatives; no tender offer was indicated. » Más en de.investing.com


  • Avadel Pharmaceuticals: Morgan Stanley reports purchase and sale of 327 shares

    Morgan Stanley & Co. International plc stated in a mandatory notification to the Irish Takeover Panel that on 14 January 2026 it, as an exempt principal trader, acquired and subsequently disposed of 327 ordinary shares of Avadel Pharmaceuticals. The transactions took place at prices between $21.4931 and $21.5440 per share. The disclosure notes a connection between Morgan Stanley and Avadel Pharmaceuticals; no additional derivative transactions or options were reported. The filing was made under Rule 38 of the Irish Takeover Rules to ensure transparency in potential takeover situations. » Más en de.investing.com


  • FIL reports 3.14% stake in Avadel Pharmaceuticals

    FIL and its subsidiaries hold a total of 3,063,023 ordinary shares of Avadel Pharmaceuticals as of the record date January 13, 2026, representing a 3.14% stake. The mandatory notification also cites a recent transaction to purchase 80,000 ordinary shares at USD 21.50 each. There are no agreements or option arrangements between the reporting parties and other companies; the holding was disclosed under Rule 8.3 of the Irish Takeover Panel. » Más en de.investing.com

Datos financieros de la empresa

En el último trimestre, Avadel Pharmaceuticals ADR tuvo unos ingresos de 66,01 M € y un beneficio neto de 17,04 mil €
(EUR) sep 2025
YoY
Ingresos 66,01 M -
Beneficio bruto 68,57 M -
Beneficio neto 17,04 mil -
EBITDA 3,05 M -

Datos fundamentales

Métrica Valor
Capitalización bursátil
1833,23 M €
Número de acciones
98,15 M
Máximo/mínimo de 52 semanas
20,34 € - 5,51 €
Dividendos No
Beta
1,31
Ratio P/E
431,08
Ratio PEG
0,66
Ratio P/B
21,39
Ratio P/S
10,72

Perfil de la empresa

Avadel Pharmaceuticals plc ist als biopharmazeutisches Unternehmen in den Vereinigten Staaten tätig. Sein führender Produktkandidat ist FT218, eine Formulierung von Natriumoxybat, die sich in einer klinischen Phase-3-Studie zur Behandlung von exzessiver Tagesschläfrigkeit und Kataplexie bei Erwachsenen mit Narkolepsie befindet. Das Unternehmen war früher unter dem Namen Flamel Technologies SA bekannt und änderte im Januar 2017 seinen Namen in Avadel Pharmaceuticals plc. Avadel Pharmaceuticals plc wurde im Jahr 2015 gegründet und hat seinen Hauptsitz in Dublin, Irland.

Nombre
Avadel Pharmaceuticals ADR
CEO
Gregory J. Divis Jr.
Sede Dublin,
Estados Unidos
Sitio web
Sector
Materiales
Industria
Productos químicos
Salida a bolsa
07/06/1996
Empleados 188

Símbolos bursátiles

Bolsa Símbolo
NASDAQ
AVDL
🍪

Parqet  usa cookies. Más información